Caribou Biosciences develops CRISPR genome-edited, allogeneic CAR-T cell therapies for hematologic malignancies. Company updates center on vispacabtagene regedleucel, or vispa-cel, an anti-CD19 CAR-T therapy being evaluated in B cell non-Hodgkin lymphoma and large B cell lymphoma, and CB-011, an anti-BCMA CAR-T therapy for relapsed or refractory multiple myeloma.
Recurring announcements include clinical and translational data from the ANTLER and CaMMouflage trials, FDA designations and trial-design interactions, financial results, research and development spending, cash resources, pipeline prioritization, and medical or investor conference participation.
Caribou Biosciences (Nasdaq: CRBU) has appointed Dr. Terri Laufer to its scientific advisory board. Dr. Laufer is an immunologist and rheumatologist with over 35 years of experience in autoimmune disease research. She is an emeritus associate professor at the Perelman School of Medicine and practices at Penn Presbyterian Medical Center and Philadelphia VA Medical Center. Her expertise will support Caribou's GALLOP clinical program, which evaluates CB-010 for lupus. Dr. Laufer's research focuses on T cell development and MHC/HLA class II-positive antigen-presenting cells. She holds degrees from Princeton and Columbia University and completed postdoctoral research at Harvard.
Caribou Biosciences presented promising clinical data from its CB-010 ANTLER Phase 1 trial at the 2024 ASCO Annual Meeting. CB-010, an allogeneic CAR-T cell therapy with partial HLA matching, showed potential to rival currently approved autologous CAR-T therapies in safety and efficacy. The trial results indicated a median progression-free survival (PFS) of 14.4 months in patients with ≥4 HLA matches, compared to 2.8 months for those with ≤3 matches. CB-010 was well tolerated with no Grade 3 or higher cytokine release syndrome or graft-versus-host disease observed. Caribou plans to enroll ~20 additional patients to confirm these findings, with initial data expected in H1 2025. A pivotal Phase 3 trial is anticipated to start in H2 2025, pending confirmation of improved outcomes.
Caribou Biosciences (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing company, announced its upcoming participation in key events. On June 2, 2024, the company will host a webcast at 7:00 pm CDT, discussing CB-010 ANTLER Phase 1 trial data in relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) from the 2024 ASCO Annual Meeting. The presentation will include insights from notable figures in hematology and oncology. Additionally, Caribou will present at the Jefferies Global Healthcare Conference on June 5, 2024, and participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on June 12, 2024. Webcasts for these events will be available on the Caribou website for 30 days.
Precision BioSciences, Inc. (Nasdaq: DTIL) reported their first quarter 2024 financial results and provided a business update. The company is focused on advancing its wholly owned gene editing programs for Hepatitis B virus and primary mitochondrial myopathy. Precision also exercised the option to return three preclinical programs for internal development or with partners. They monetized CAR T assets through licensing deals and completed a $40 million common stock offering to extend cash runway into H2 2026. Financially, Precision had $137.8 million in cash and cash equivalents as of March 31, 2024, with total revenues of $17.6 million for the quarter. Research and development expenses increased to $13.3 million, while general and administrative expenses decreased to $8.4 million. Net income from continuing operations was $8.6 million for the quarter.
Caribou Biosciences, Inc. (Nasdaq: CRBU) reported its first quarter 2024 financial results and pipeline progress, highlighting advancements in clinical-stage programs for hematologic malignancies and autoimmune diseases. With $345.9 million in cash, cash equivalents, and marketable securities, the company expects to fund operations into Q1 2026. Notable milestones include presenting clinical data at the 2024 ASCO Annual Meeting, initiating the GALLOP Phase 1 trial, and providing updates on ongoing trials. Despite a slight decrease in licensing and collaboration revenue, increased R&D and G&A expenses led to a net loss of $41.2 million for Q1 2024.
Caribou Biosciences, Inc. (Nasdaq: CRBU) will participate in upcoming investor conferences, including the 2024 RBC Capital Markets Global Healthcare Conference and BofA Securities 2024 Health Care Conference. The company will present at these events, offering webcasts for more information.
Summary not available.
Summary not available.
Summary not available.
Summary not available.